Core Viewpoint - 恒瑞医药's performance continues to show double-digit growth driven by innovative drug licensing agreements, with significant revenue contributions from upfront payments [1] Group 1: Financial Performance - In the first three quarters of this year, 恒瑞医药 achieved revenue of 23.188 billion yuan, an increase of 14.85% [1] - The net profit attributable to shareholders reached 5.751 billion yuan, reflecting a growth of 24.50% [1] - The upfront payments from innovative drug licensing exceeded 800 million USD, contributing over 20% to the company's revenue [1] Group 2: Licensing Agreements - In the third quarter alone, 恒瑞医药 completed three licensing agreements, including a notable collaboration with GSK in July, which involved the development of up to 12 innovative drugs [1] - The agreement with GSK provided an upfront payment of 500 million USD, with potential total payments of approximately 12 billion USD [1] Group 3: Internationalization Strategy - 恒瑞医药's global R&D president emphasized a two-step strategy for internationalization: first, leveraging partnerships for market entry, and second, focusing on independent development of high-quality products [2] - The company is currently expanding its production capacity and improving product quality while pursuing internationalization [2] Group 4: R&D Investment - In the first three quarters, 恒瑞医药's R&D expenses reached 4.945 billion yuan, with cumulative R&D investment exceeding 50 billion yuan [3] - The company has a robust pipeline with over 100 innovative products in clinical development and more than 400 clinical trials ongoing domestically and internationally [3] - As of the end of the third quarter, 恒瑞医药's cash reserves amounted to 40.364 billion yuan, bolstered by recent financing from its Hong Kong listing [3]

Core Insights - The global life sciences industry is increasingly seeking strategic partnerships with Chinese biopharmaceutical companies to access innovative products and technologies amid macroeconomic challenges and the approaching patent cliff [1][2] - In the first half of 2025, Chinese pharmaceutical companies entered into 61 cooperation deals with multinational companies, with transaction amounts for local assets reaching $48.5 billion, surpassing the total of $44.8 billion for the entire year of 2024 [1][2] - The partnership between Hengrui Medicine and GlaxoSmithKline (GSK) exemplifies this trend, involving the joint development of up to 12 innovative drugs, with GSK paying a total upfront fee of $500 million [1][4] Industry Trends - China's share of global innovative drug business development (BD) transactions has increased significantly, from 3% in 2019 to 13% in 2024, with transaction amounts rising from 1% to 28% [2] - In the first half of 2025, the total amount of license-out transactions for Chinese innovative drugs approached $66 billion, indicating sustained interest from multinational pharmaceutical companies in Chinese assets [2] Company Strategies - Hengrui Medicine employs a strategy that combines core product licensing with platform licensing, focusing on both a leading product (HRS-9821) and options for up to 11 additional projects across various therapeutic areas [4][5] - The company adheres to strict selection criteria for its BD projects, emphasizing "best-in-class" or "first-in-class" potential [4][5] - Hengrui's R&D investment reached 3.871 billion yuan in the first half of 2025, with innovative drug sales and licensing income accounting for 60.66% of total revenue [6][7] Challenges and Opportunities - Chinese innovative drug companies face challenges in internationalization, including the need to align clinical trial designs with local treatment protocols and understand local regulations and healthcare policies [9][10] - Despite high costs associated with overseas clinical trials, the potential returns are significant, supported by strong execution capabilities and quality platforms within Chinese companies [10][11] - The market response to Hengrui's partnership with GSK was positive, with the company's stock price hitting the limit up and total market value exceeding 400 billion yuan, reflecting market confidence in its BD strategy [11]

Group 1: Fund Performance and Holdings - The performance of several high-performing funds has been highlighted, with notable increases in their asset sizes, such as Zhonghang Opportunity Navigator reaching 13.23 billion yuan, a nearly 12-fold increase from the previous quarter [2][4] - Yongying Medical Innovation Select reported a 157.28% growth in size, reaching 7.83 billion yuan by the end of Q3 [2][6] - The top holdings of these funds include significant stocks in the AI computing and innovative pharmaceutical sectors, with many stocks experiencing substantial price increases this year [3][6] Group 2: Investment Focus Areas - Zhonghang Opportunity Navigator focuses on the AI computing industry, with a stock position of 88.56% and significant increases in holdings of key stocks like Huadian Co., which saw a 669.13% increase in shares held [3][4] - Yongying Medical Innovation Select emphasizes innovative pharmaceuticals, with top holdings exceeding 700 million yuan, and several stocks seeing their holdings double compared to the previous quarter [6][7] - Penghua Carbon Neutral Theme Fund is investing in manufacturing, new energy, and new technologies, achieving a profit of 3.33 billion yuan in Q3 [9][10] Group 3: Market Outlook - The long-term growth potential of AI computing is emphasized, with expectations for a technology cycle lasting at least 5 to 10 years, particularly in robotics and new industrial applications [11][12] - The innovative pharmaceutical sector is viewed as a strong investment theme, with potential for significant returns as domestic innovations gain global competitiveness [8][6] - The overall market outlook remains optimistic despite potential pressures from trade disputes, with expectations for stable economic performance in the fourth quarter [15]

Group 1 - The MSCI China Healthcare Index has increased by 58.6% since the beginning of 2025, outperforming the MSCI China Index by 24.2% [1] - The recent slight pullback in the healthcare sector (10% since October) presents a buying opportunity, driven by a recovery in capital market financing and an increase in the scale of innovative drug exports [1] - The CXO industry is expected to see performance recovery in the second half of 2025 due to the anticipated interest rate cuts in the U.S. [1] Group 2 - Significant clinical data was released at the ESMO conference, highlighting key drugs such as SKB264, which shows statistical significance in overall survival for NSCLC patients resistant to EGFR-TKI [2] - The mPFS for lvonescimab in first-line sqNSCLC was reported at 11.1 months, compared to 6.9 months for the control group [2] - The uORR for drug 707 from 三生制药 in first-line colorectal cancer reached 82.6%, indicating strong efficacy [2] Group 3 - The impact of business development (BD) on stock prices is diminishing, prompting a focus on the clinical advancement of authorized pipelines overseas [3] - 信达生物 has entered a global strategic partnership with Takeda for IBI363, sharing 40% of global R&D costs and U.S. commercial rights, reflecting confidence in the drug and commitment to globalization [3] - The company anticipates that clinical progress will serve as a catalyst for stock price increases, with most value realization dependent on successful commercialization rather than upfront payments from licensing deals [3]

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the healthcare sector, including BeiGene, WuXi AppTec, and Innovent Biologics, among others. A "Neutral" rating is given to Sinopharm Group [1]. Core Insights - The CXO sector has shown strong growth, with a 5.2% increase, while the innovative drug sector has been relatively weak, declining by 3.4% [5][30]. - The Hang Seng Healthcare Index has increased by 73.4% year-to-date, outperforming the Hang Seng Index by 43.3 percentage points [4][29]. - Recent strategic partnerships, such as the one between Innovent Biologics and Takeda, highlight the growing international competitiveness of Chinese pharmaceutical companies [6][31]. Summary by Sections Market Performance - The Hang Seng Healthcare Index fell by 0.8% during the week of October 20-24, 2025, underperforming the Hang Seng Index by 4.5 percentage points [4][29]. - The top-performing sectors included CXO/Research Services (+5.2%) and Pharmaceutical Distribution (+4.2%), while Biotech and Pharma sectors saw declines of 3.1% and 3.4%, respectively [5][30]. Strategic Developments - Innovent Biologics and Takeda reached a global strategic cooperation agreement worth $11.4 billion, marking a significant milestone in the international collaboration of Chinese pharmaceutical companies [10][31]. - Gushengtang announced a partnership with the Singaporean digital healthcare platform 1doc to introduce traditional Chinese medicine services in Singapore [15][35]. Future Outlook - The report emphasizes the importance of tracking the trend of "quality and quantity improvement" in the overseas expansion of Chinese innovative drugs, indicating a positive outlook for co-development initiatives [6][31]. - The medical service sector is currently at a valuation bottom, with expectations for improvement as domestic demand signals strengthen [7][32].

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical and biotechnology industry, but it highlights significant developments that may influence future ratings [1]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 0.58%, underperforming compared to the Wind All A index (3.47%) and the CSI 300 index (3.24%) [2][7]. - A major strategic collaboration was announced between Innovent Biologics and Takeda Pharmaceutical, with a total deal value potentially reaching $11.4 billion, including an upfront payment of $1.2 billion and milestone payments of up to $10.2 billion [2][10]. - The report emphasizes the importance of the upcoming commercial insurance innovative drug directory, which is expected to be released soon, and suggests monitoring the companies that will be included [2][11]. Weekly Market Review - The pharmaceutical and biotechnology sector's performance was mixed, with medical research outsourcing (5.47%), offline pharmacies (2.99%), and pharmaceutical distribution (1.97%) leading the gains, while other biological products (-1.91%), traditional Chinese medicine (-0.85%), and chemical preparations (-0.41%) lagged behind [2][7]. - Notable stock performances included Teva Pharmaceutical (22.3%), Bid Pharma (18.9%), and *ST Jingfeng (16.6%) as top gainers, while Tuo Jing Life (-18.6%), Xin Nuo Wei (-17.5%), and Shuo Tai Shen (-14.9%) were the biggest losers [2][10]. Industry News and Key Company Announcements - Innovent Biologics announced a significant global strategic partnership with Takeda to accelerate the development of new therapies, including three key drug candidates [2][10]. - Kangfang Biologics' AK112 injection has been proposed for inclusion in breakthrough therapy designation for treating triple-negative breast cancer [2][11]. - Summit Therapeutics announced a $500 million private placement to fund the clinical development of its drug candidate [2][11]. - Ipsen and ImCheck Therapeutics reached a final agreement for a €1 billion acquisition focused on a first-in-class monoclonal antibody for acute myeloid leukemia [2][13]. - Moderna decided to terminate the development of its CMV mRNA vaccine after failing to meet primary endpoints in a Phase III trial [2][13].

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The report highlights the significant collaboration between Innovent Biologics and Takeda Pharmaceutical, which is seen as a positive trend for Chinese innovation going global. The deal includes an upfront payment of $1.2 billion and potential milestone payments, with a total deal value reaching up to $11.4 billion [2] - The report notes a surge in License-out transactions, with 103 deals and a total value of $92.03 billion in the first three quarters of 2025, marking a 77% increase compared to the total for 2024 [2] - The report emphasizes the recovery of the CDMO sector, with companies like Jiuzhou Pharmaceutical and Boteng achieving significant revenue growth in Q3 2025, indicating a positive trend in the industry [3] - The medical device market is showing a steady recovery, with a 29.8% year-on-year growth in the overall bidding market for medical devices in Q3 2025 [4] - The report discusses the increasing trend of oral immunomodulatory drugs, particularly in the treatment of psoriasis, with Johnson & Johnson's acquisition of Protagonist Therapeutics being a notable example [5] - The report also highlights the trends in respiratory infectious diseases, with an expected increase in cases in the coming months, which may impact medical testing and treatment medications [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry has underperformed compared to the CSI 300 index, with a recent weekly decline of 0.95% and a monthly decline of 3.28% [21][25] 2. Pharmaceutical Sector Performance and Valuation - The pharmaceutical sector's recent performance has been below the CSI 300 index, with a 1-month decline of 3.28% and a 3-month increase of only 1.75% [39][42] 3. Recent Research Achievements - The report lists various recent research outputs from the team, including deep dive reports on the growth of the blood products industry and the potential of GLP-1 drugs [47] 4. Recent Industry Policies and News - The report outlines significant recent policies, including the promotion of instant settlement reforms by the National Medical Insurance Administration and the regulation of clinical research for biomedical technologies [49] - Recent news highlights include major collaborations and drug approvals, such as the partnership between Innovent Biologics and Takeda, and the approval of new drugs by various companies [50][51]

Core Insights - Over 90% of actively managed equity funds reported profits, with many experiencing significant growth in scale during the third quarter [1][2] - The equity market's heat is reflected in both fund performance and scale, with a notable increase in stock positions among funds [1][2] Fund Performance and Scale - As of October 26, 1062 fund products have disclosed their third-quarter reports, with nearly 60% being equity funds [2] - More than 60% of active equity funds maintained stock positions above 90%, and over 96% achieved positive returns in Q3 [2][3] - Notable performers include Yongying Technology Select A, which saw a year-to-date return exceeding 206% and a quarterly return of 99.74% [2][3] Explosive Growth in Fund Scale - Yongying Technology Select A experienced a net subscription of 2.766 billion units, increasing its scale from 1.166 billion to 11.521 billion, an increase of nearly 888% [3] - Other funds like Zhongou Digital Economy also saw significant scale increases, with net subscriptions pushing its scale from 1.527 billion to over 13 billion, a growth of 7.5 times [3] - Over 80% of funds reported a quarter-on-quarter increase in scale, with 37 funds doubling their size [3] Sector Rotation and Fund Manager Strategies - Fund managers are actively adjusting their portfolios in response to market conditions, particularly in the technology sector [4][5] - Yongying Technology Select A's stock holdings exceeded 94%, focusing on global cloud computing, with significant increases in major holdings [5] - Zhongou Digital Economy made more pronounced adjustments, retaining only a few previous top holdings while introducing new ones [5][6] Technology Sector Insights - Fund manager Feng Ludan reduced exposure to AI infrastructure while increasing allocations to intelligent robotics and C-end internet platforms [6] - The global cloud computing industry remains a focal point for investment, with expectations of increased AI model value [6] Pharmaceutical Sector Trends - The pharmaceutical sector, particularly innovative drugs, remains a key focus despite recent market fluctuations [7][8] - Longcheng Pharmaceutical Industry Select A reported a year-to-date return of 84.81%, maintaining a strong position in the industry [7] - Fund managers are adjusting their portfolios to focus on high-value innovative drug stocks, emphasizing cost-effectiveness and certainty [8][9]

每经记者｜林姿辰 每经编辑｜魏文艺 "全世界也找不出第二家公司，像恒瑞医药有这么完整的布局⋯⋯那么，出海的标准是什么？" 10月26日，恒瑞医药全球研发总裁张连山在第十届医药创新与投资大会上向包括《每日经济新闻》记者 在内的媒体表示，创新药出海的首要前提是认清产品的差异化价值，并非只有First-in-Class（同类首 创）才能打开海外市场，如果产品能跻身前三或前五梯队，具备足够的临床差异化优势，同样能获得海 外企业的认可，由此促成的BD（商务拓展）合作，是恒瑞医药出海的第一步。 第二步，是推动优质产品的海外自主开发。张连山表示，对于部分具备明确临床价值，但尚未进入海外 药企重点布局范围的新药，恒瑞医药会依托在中国已积累的临床数据，以相对较低的研发投入，推动其 在海外的临床试验与上市申报。 "这是国际化的两步，第一步借船出海，第二步还是要回归到造船出海，为创新产品的价值实现画了一 个句号，这是目前公司出海的大概策略。"张连山表示，自己不会给出突破性进展的时间表，"因为做药 是Science（科学），有很多不确定性，今天好了，明天可能死掉了，很多产品在三期（临床试验）失 败的可能性比较小，但还是有的。我们还是 ...

Core Viewpoint - The article highlights the accelerated pace of Chinese innovative pharmaceuticals entering international markets, with a comprehensive recovery in the healthcare industry observed in both primary and secondary markets this year [1]. Group 1: Market Dynamics - Overseas investors are showing a steady increase in interest towards Chinese healthcare companies, with more institutions willing to participate as cornerstone investors in Hong Kong IPOs [2][6]. - The capital market is experiencing a revival, with frequent financing activities and an increase in out-licensing projects, providing strong support for industry development [6][10]. - In the first half of the year, there were 677 financing transactions in the domestic healthcare primary market, totaling over 50 billion yuan, a year-on-year increase of 10% [6]. Group 2: Investment Trends - Investment focus is shifting from financial metrics to technological innovation capabilities, particularly in innovative drugs, medical devices, and artificial intelligence [6][10]. - The return of global funds is partly driven by the successful IPO of Ningde Times and the strong performance of companies like Hengrui Medicine, which has boosted investor confidence [7][10]. Group 3: Challenges in International Expansion - Chinese innovative pharmaceutical companies face challenges in their international expansion, including the risk of collaboration termination and regulatory hurdles, particularly in adapting to FDA requirements [8][10]. - Intellectual property issues are also critical, as some transactions have failed due to IP concerns [8]. Group 4: Enhanced Bargaining Power - Chinese pharmaceutical companies have significantly improved their bargaining power in the global value chain, with international collaborations expanding in breadth and depth [10]. - This enhanced bargaining power is reflected in improved deal terms, including higher upfront payments and more diverse transaction models [10]. Group 5: Future Outlook - The investment and financing activity in the healthcare sector is expected to continue, supported by the ongoing development of the industry and the increasing value of international investment banks' services [11][12]. - The trend of overseas funding returning is still in its early stages, with potential for further liquidity improvements [12]. - The industry is moving towards maturity and globalization, with a growing number of local companies transitioning from followers to key players on the global stage [13].